Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

VICTORIA

Projekt: Typer af projekterProjekt

  1. Miracle D6402C00001

    Projekt: Typer af projekterProjekt

  2. ASSESS-CKD

    Projekt: Typer af projekterProjekt

  3. Finearts-HF

    Projekt: Typer af projekterProjekt

  4. Empulse

    Projekt: Typer af projekterProjekt

  5. Satellite

    Projekt: Typer af projekterProjekt

  6. ORION-8

    Projekt: Typer af projekterProjekt

  7. Determine 01 (HFpEF)

    Projekt: Typer af projekterProjekt

Vis graf over relationer
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF
StatusIgangværende
Periode01/12/201601/01/2020
URLNCT02861534

ID: 49755167